Skip to content

Study · Animal study (in vivo) · mouse · 2025

1 result

Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening.

Patai R, Patel K, Csik B, Gulej R, Nagaraja RY, Nagy D, Chandragiri SS, Shanmugarama S, Kordestan KV, Nagykaldi M, Ekambaram S, Ungvari A and 6 more

Show all authors

Yabluchanskiy A, Tarantini S, Benyo Z, Csiszar A, Ungvari Z, Nyul-Toth A

GeroScience2 Apr 2025Cited by 10 (Europe PMC)

PMID40169521 (opens in a new tab)PMCIDPMC12181615 (opens in a new tab)DOI10.1007/s11357-025-01634-5 (opens in a new tab)PepBankPUB-40169521
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Cerebral microhemorrhages (CMHs, also known as cerebral microbleeds) contribute to vascular cognitive impairment and dementia (VCID), with aging and hypertension being key risk factors. Mitochondrial oxidative stress is a hallmark of cerebrovascular aging, leading to endothelial dysfunction. This study tests the hypothesis that increased mitochondrial oxidative stress contributes to age-related CMH susceptibility and evaluates the mitochondrial-targeted antioxidative peptide SS-31 (elamipretide) as a potential protective agent in an aged, hypertensive mouse model. Concurrently, we developed a high-throughput, machine learning-driven imaging pipeline to enhance CMH quantification and facilitate the screening of anti-aging vasoprotective interventions. To detect CMHs, brain sections were labeled with diaminobenzidine (DAB) and digitized using a slide scanner-based imaging platform. We developed multiple quantification tools, including color space transformation for enhanced contrast separation and a supervised machine-learning approach utilizing a random forest algorithm to generate whole-brain 3D reconstructions and precisely localize CMHs. We optimized a semi-automated detection method integrating color space transformation and machine learning, benchmarking it against traditional manual counting and color deconvolution-based approaches. While SS-31 treatment did not significantly mitigate hypertension-induced CMH burden in aged mice, our high-throughput imaging pipeline provided a reliable, scalable, and unbiased approach to CMH detection, reducing processing time while improving accuracy. This methodological advancement paves the way for future preclinical studies evaluating therapeutic strategies for cerebrovascular protection in aging. Our findings underscore the need for multi-targeted interventions to mitigate CMH-related neurovascular impairments and prevent VCID.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In aged hypertensive mice, SS‑31 did not significantly reduce the burden of cerebral microhemorrhages.

    In plain wordsIn aged mice with high blood pressure, SS‑31 did not clearly reduce small brain bleeds.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeHypertension-induced cerebral microhemorrhage burden
    Study

    mousen: not reported in source

    aged hypertensive mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While SS-31 treatment did not significantly mitigate hypertension-induced CMH burden in aged mice
    1 context sentence
    Summary · context
    This study tests the hypothesis that increased mitochondrial oxidative stress contributes to age-related CMH susceptibility and evaluates the mitochondrial-targeted antioxidative peptide SS-31 (elamipretide) as a potential protective agent in an aged, hypertensive mouse model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.